Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

PharmaCyte Biotech (PMCB) Equity Average (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Equity Average for 15 consecutive years, with $39.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average fell 13.53% to $39.4 million in Q4 2025 year-over-year; TTM through Oct 2025 was $39.4 million, a 13.53% decrease, with the full-year FY2025 number at $39.8 million, down 20.73% from a year prior.
  • Equity Average was $39.4 million for Q4 2025 at PharmaCyte Biotech, down from $47.7 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $91.7 million in Q1 2022 to a low of $6.2 million in Q3 2021.
  • A 5-year average of $49.7 million and a median of $45.8 million in 2024 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: surged 1322.03% in 2022, then crashed 60.6% in 2024.
  • PharmaCyte Biotech's Equity Average stood at $48.9 million in 2021, then skyrocketed by 71.03% to $83.7 million in 2022, then plummeted by 54.6% to $38.0 million in 2023, then grew by 20.01% to $45.6 million in 2024, then dropped by 13.53% to $39.4 million in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Equity Average are $39.4 million (Q4 2025), $47.7 million (Q3 2025), and $46.1 million (Q2 2025).